Q3 EPS Estimates for XOMA Royalty Reduced by Leerink Partnrs

XOMA Royalty Corporation (NASDAQ:XOMA) – Research analysts at Leerink Partnrs lowered their Q3 2025 earnings per share estimates for XOMA Royalty in a note issued to investors on Thursday, August 14th. Leerink Partnrs analyst D. Risinger now forecasts that the biotechnology company will post earnings of ($0.02) per share for the quarter, down from their previous estimate of $0.03. The consensus estimate for XOMA Royalty’s current full-year earnings is ($1.41) per share. Leerink Partnrs also issued estimates for XOMA Royalty’s Q4 2025 earnings at $0.05 EPS, FY2025 earnings at $0.52 EPS, FY2027 earnings at $1.68 EPS, FY2028 earnings at $4.18 EPS and FY2029 earnings at $6.04 EPS.

Several other research firms have also recently issued reports on XOMA. Zacks Research raised XOMA Royalty to a “hold” rating in a research report on Tuesday, August 12th. HC Wainwright reaffirmed a “buy” rating and set a $104.00 price target on shares of XOMA Royalty in a report on Wednesday, May 28th. Finally, Wall Street Zen upgraded XOMA Royalty from a “hold” rating to a “buy” rating in a report on Monday, August 11th.

XOMA Royalty Price Performance

Shares of NASDAQ XOMA opened at $31.37 on Monday. The company has a 50 day simple moving average of $26.41 and a two-hundred day simple moving average of $24.32. XOMA Royalty has a fifty-two week low of $18.35 and a fifty-two week high of $35.00. The company has a market capitalization of $379.26 million, a price-to-earnings ratio of -20.24 and a beta of 1.00. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.88 and a current ratio of 4.88.

XOMA Royalty (NASDAQ:XOMA) last announced its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.60. The company had revenue of $13.13 million for the quarter, compared to the consensus estimate of $9.39 million. XOMA Royalty had a positive return on equity of 2.63% and a negative net margin of 27.57%.

Institutional Investors Weigh In On XOMA Royalty

Several large investors have recently bought and sold shares of the business. GAMMA Investing LLC lifted its stake in XOMA Royalty by 1,063.8% in the first quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 1,585 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of XOMA Royalty by 203.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,523 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in XOMA Royalty by 38.0% during the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock valued at $113,000 after acquiring an additional 1,183 shares during the period. JPMorgan Chase & Co. boosted its holdings in XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 543 shares during the period. Finally, Raymond James Financial Inc. bought a new position in XOMA Royalty in the 2nd quarter valued at $116,000. Institutional investors own 95.92% of the company’s stock.

Insider Buying and Selling at XOMA Royalty

In related news, CEO Owen Hughes sold 25,637 shares of XOMA Royalty stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $25.38, for a total transaction of $650,667.06. Following the sale, the chief executive officer owned 62,701 shares of the company’s stock, valued at approximately $1,591,351.38. This trade represents a 29.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 7.20% of the company’s stock.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.